Table 1 Proteolytic enzymes, CEA and CA 19-9 in patients with colorectal cancer, ulcerative colitis, adenoma and controls.

Colorectal cancer (n = 56)

8.75*§

(2.4–39.3)

1.10*§

(1.0–35.3)

0.29*§

(0.1–0.79)

52.45*§

(13.5–138.6)

2.40

(0.4–235.0)

9.15

(1.0–540.0)

Ulcerative colitis

(n = 25)

4.37

(2.8–7.2)

1.10

(1.0–1.7)

0.20

(0.18–0.23)

12.60

(8.8–17.6)

3.15

(0.8–11.5)

9.00

(4.5–32.0)

Colorectal adenoma (n = 26)

4.45#

(4.2–10.3)

1.25#

(1.0–6.5)

0.20

(0.16–0.53)

14.05#

(10.5–65.5)

3.55

(0.7–5.7)

10.27

(3.7–41.0)

Controls

(n = 35)

3.80

(1.4–5.8)

1.00

(1.0–2.1)

0.19

(0.16–0.27)

10.70

(1.87–23.8)

2.90

(0.8–18.9)

8.90

(1.27–47.4)

Kruskall-Wallis analysis of variance (P value)

P < 0.0001

P < 0.0001

P < 0.0001

P < 0.0001

P = NS

P = NS